Real-world palbociclib effectiveness in patients with metastatic breast cancer: Focus on neutropenia-related treatment modification strategies and clinical outcomes-Reference-Cited by-同舟云学术

Real-world palbociclib effectiveness in patients with metastatic breast cancer: Focus on neutropenia-related treatment modification strategies and clinical outcomes

Published:2023 Issue: Volume:35 Page:100691
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

Hackert Mariska Q.N.^ORCID,van Uden-Kraan Cornelia F.,Agterof Mariette J.,van der Velden Annette W.G.,Vriens Birgit E.P.J.,Janssen Johan J.B.,Geenen Maud,van der Padt-Pruijsten Annemieke,van de Garde Ewoudt M.W.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for adverse events: results of a questionnaire-based study;Basch;Lancet Oncol.,2006

2. Real-world effectiveness of palbociclib versus clinical trial results in patients with advanced /metastatic breast cancer that progressed on previous endocrine therapy;Bui;Breast Cancer: Basic Clin. Res.,2019

3. Real-world evidence and real-world data for evaluating drug safety and effectiveness;Corrigan-Curay;JAMA,2018

4. Development and evaluation of a real-world outcomes-based tool to support informed clinical decision making in the palliative treatment of patients with metastatic NSCLC;Cramer-van der Welle;Clin. Cancer Inform.,2021

5. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database;International Journal of Cancer;2023-10-13